TL;DR
These results demonstrate that liposomal peptide formulations are an effective strategy for enhancing the immunogenicity of HCV B-cell epitopes and provide a promising foundation for the development of a multi-epitope hepatitis C vaccine.
Background Hepatitis E virus (HEV) is one of the leading causes of acute and chronic hepatitis among humans across the globe and is linked to severe diseases in immunocompromised individuals and pregnant women. Despite its substantial global burden, only one vaccine is licensed (in China and Pakistan), limiting its glo...
A major goal for hepatitis C virus (HCV) vaccine development is to elicit broadly neutralizing antibodies (bNAbs) against the E1E2 glycoprotein complex located on the viral surface. Inducing HCV bNAbs requires engagement of their germline B cell precursors. HCV glycoproteins usually do not bind and activate inferred ge...
This study identifies a novel, highly conserved with conservative substitutions linear B-cell epitope on the RABV glycoprotein, providing a precise molecular target for the rational design of next-generation epitope-based vaccines and specific diagnostic tools.
The findings demonstrate the feasibility of consensus-based NS1 antigen design for broad serotype coverage and support the further development of NS1-based immunogens as complementary components of next-generation dengue vaccines.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
